Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAN2355
- Development stage
- Preclinical
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SAN2355 is a **selective small molecule activator** of Kv7.2/Kv7.3 potassium channels, developed for the treatment of epilepsy and potentially other neurological disorders. Unlike previous non-selective Kv7 activators such as retigabine and Potiga, SAN2355 precisely targets Kv7.2/Kv7.3 subunits, which are key for seizure suppression, and avoids activation of Kv7.4 and Kv7.5. This selectivity is intended to improve efficacy and reduce adverse effects—such as urinary retention and CNS side effects—that limited the clinical use of earlier Kv7-targeting drugs. SAN2355 uses novel chemistry to avoid safety liabilities linked to the aniline-moiety found in older Kv7 activators. Currently, it is in preclinical development, with plans to enter Phase 1 clinical trials by Q3 2025[1][2][3][5][7][9][10].
- Brand names
- SAN2355SAN-2355SAN 2355
- Other names
- SAN2355SAN-2355SAN 2355
02
Targets
KCNQ (Potassium voltage-gated channel subfamily Q (Kv7))KCNQ5 (Potassium voltage-gated channel subfamily KQT member 5)
Beyond the preview
Go deeper on SAN2355.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAN2355.